Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis

Hung-Yang Kuo, Ta-Chen Huang, Chien-Huai Chuang, Tsung-Che Wu, Yen-Lin Huang, Chia-Chi Lin, Jang-Ming Lee, Jhe-Cyuan Guo, Chih-Hung Hsu · 2026

Read Cabozantinib and atezolizumab for recurrent or metastatic esophageal squamous cell carcinoma after platinum-based chemotherapy failure: a single-arm phase II study and biomarker analysis by Hung-Yang Kuo, Ta-Chen Huang, Chien-Huai Chuang, Tsung-Che Wu, Yen-Lin Huang, Chia-Chi Lin, Jang-Ming Lee, Jhe-Cyuan Guo, Chih-Hung Hsu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13323437.txt.

Description

Hung-Yang Kuo, Ta-Chen Huang, and Chien-Huai Chuang lead a team testing a two-drug pairing for esophageal cancer that returned after platinum chemotherapy. Their phase two study appeared in two thousand twenty-six. Immune checkpoint drugs alone help few such patients. A multikinase drug that starves tumors and stirs immunity might widen the benefit.

Twenty-four patients received the daily kinase pill plus an immune infusion every three weeks. About three in ten saw their tumors shrink. Over half achieved at least disease control for a time. Responses lasted a median of several months. Biomarker analyses accompanied the treatment data. Toxicity was tracked as a formal endpoint. As a single-arm study it cannot prove the pairing beats either drug alone. It does clear the bar for a randomized test. Esophageal patients after platinum failure have thin options.

Catalog record

CREATORHung-Yang Kuo, Ta-Chen Huang, Chien-Huai Chuang, Tsung-Che Wu, Yen-Lin Huang, Chia-Chi Lin, Jang-Ming Lee, Jhe-Cyuan Guo, Chih-Hung Hsu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13323437

Browse the full library · About the Tower of Babel